Scientific Programme

For the final programme please click here:




o    THURSDAY, OCTOBER 18, 2018

For the programme of the GPOH-Tag please click here:

GPOH Programme


o    FRIDAY, OCTOBER 19, 2018

Friday, October 19, 2018
08:45 - 09:00Welcome
09:00 -10:30Session 01: Plasticity versus heterogeneity and evolution in pediatric cancers
 Chairs: D. Gisselsson, Lund (SE); R. Abbasi, Vienna (AT)
09:00 - 09:30Keynote Lecture 01. Evolutionary trajectories of childhood cancer over time and space
D. Gisselsson, Lund (SE)
09:30 - 09:45S01.1 Developmental Hierarchy in Langerhans Cell Histiocytosis
C. Hutter, Vienna (AT)
09:45 - 10:00S01.2 Common oncogenic mechanisms for FET fusion-oncoproteins?
P. Åman, Gothenburg (SE)
10:00 - 10:15S01.3 Proteostatic mechanisms regulate cellular plasticity in Ewing sarcoma in response to EWS-FLI1 fluctuations and provide novel opportunities for anti-metastatic treatment
J. Ban, Vienna (AT)
10:15 - 10:30S01.4 Exploiting stromal Schwann cell derived factors for targeting aggressive neuroblastoma
S. Taschner-Mandl, Vienna (AT)
10:30 - 11:00Coffee break
11:00 -12:30Session 02: In silico approaches to understand cancer biology and guide therapy
 Chairs: M. Nowak, Cambridge (US); A. Pötsch, Vienna (AT)
11:00 - 11:30Keynote Lecture 02. Evolutionary dynamics of cancer
M. Nowak, Cambridge (US)
11:30 - 11:45S02.1 Dissecting pediatric cancer with single-cell and high-throughput epigenomics
F. Halbritter, Vienna (AT)
11:45 - 12:00S02.2 Pediatric solid tumors with BCOR alterations share common molecular characteristics
J. Gojo, Vienna (AT)
12:00 - 12:15S02.3 Computing BRCAness in osteosarcoma with “genomic scar” and mutational signatures' assays. Two sides of the same coin?
M. Barenboim, Munich (DE)
12:15 - 12:30S02.4 On the origin of childhood neoplasms with chromosome counts in the uneven ploidy range
O. Haas, Vienna (AT)
12:30 - 13:15Lunch break 
13:15 - 14:30Poster walk 1
14:30 - 16:00Session 03: Novel concepts in precision medicine
 Chairs: A. Shlien, Toronto (CA); S. Köhrer, Vienna (AT)
14:30 - 15:00Keynote Lecture 03.  Clinically relevant mutational patterns in childhood cancer
A. Shlien, Toronto (CA)
15:00 - 15:15S03.1 Family based whole-exome sequencing approach of parent-child trios to elucidate the role of inherited susceptibility to childhood cancer
J. Taeubner, Düsseldorf (DE)
15:15 - 15:30S03.2 Systems biology-based analysis of DNArepair defects in primary immunodeficiencies and cancer
J. Pazmandi, Vienna (AT)
15:30 - 15:45S03.3 Phospho-profiling linking biology and clinics in acute myeloid leukaemia
M. Dworzak, Vienna (AT)
15:45 - 16:00S03.4 N-terminal CEBPA-mutant acute myeloid leukemia is hypersensitive to small-molecule-mediated inhibition of the SET/MLL complex
L. Schmidt, Vienna (AT)
16:00 - 16:30Coffee break
16:30 - 18:00Session 04: Treatment challenges in pediatric cancer
 Chairs: S. Izraeli, Tel Aviv (IL); E. Salzer, Vienna (AT)
16:30 - 17:00Keynote Lecture 04. Targeted therapy for acute lymphoblastic leukemia – promises and challenges
S. Izraeli, Tel Aviv (IL)
17:00 - 17:15S04.1 Immunotherapy with anti-GD2 antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN trial improves outcome of high-risk neuroblastoma patients compared to historical controls.
R. Ladenstein, Vienna (AT)
17:15 - 17:30S04.2 Immunotherapy with ch14.18/CHO and hu14.18-IL-2 upregulate the PD1/PD-L1 immune checkpoint in neuroblastoma: a rationale for combination therapy
H. Lode, Greifswald (DE)
17:30 - 18:00Panel Discussion
Moderator: R. Panzer, Vienna (AT)
S. Armstrong, Boston (US)
S. Izraeli, Tel Aviv (IL)
O. Haas, Vienna (AT)
G. Mann, Vienna (AT)


o    SATURDAY, OCTOBER 20, 2018

09:00 - 10:30Session 05: Innovative pediatric cancer models
 Chairs: D. Langenau, Boston (US); C. Sturtzel, Vienna (AT)
09:00 - 09:30Keynote Lecture 05. Fishing for Mechanisms of Progression and Relapse in Pediatric Cancer
D. Langenau, Boston (US)
09:30 - 09:45S05.1 Zebrafish as a platform for modeling dosage sensitive non mutated dependency genes in neuroblastoma
L. Depestel, Ghent (BE)
09:45 - 10:00S05.2 The Zebrafish platform Austria for preclinical drug screening (ZANDR) -Towards automated drug screening in vertebrate cancer models
C. Sturtzel, Vienna (AT)
10:00 - 10:15S05.3 Metastatic Ewing Sarcoma-like tumor development in mice with postnatal EWS/FLI1 induction
R. Moriggl, Vienna (AT)
10:15 - 10:30S05.4 Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemia
M. Erlacher, Freiburg (DE)
10:30 - 11:00Coffee break
11:00 -12:30Session 06: The future of targeted therapy
 Chairs: S. Armstrong, Boston (US); C. Hutter, Vienna (AT)
11:00 - 11:30Keynote Lecture 06. Targeting Epigenetic Mechanisms in Pediatric Cancers
S. Armstrong, Boston (US)
11:30 - 11:45S06.1 Unraveling the druggable interactome of EWS-FLI1 identifies differential sensitivities of Ewing sarcoma cells to apoptosis inducers
B. Radic Sarikas, Vienna (AT)
11:45 - 12:00S06.2 The ribonucleotide reductase subunit M2 (RRM2) is a druggable copy number driven dependency gene in neuroblastoma
C. Nunes, Ghent (BE)
12:00 - 12:15S06.3 Knockdown of circARID1A inhibits cell proliferation and drives differentiation in neuroblastoma
C. Danßmann, Berlin (DE)
12:15 - 12:30S06.4 A single center experience of blinatumomab in 38 pediatric patients with heavily pretreated relapsed or refractory B-cell acute lymphoblastic leukemia
M. Queudeville, Tübingen (DE)
12:30 - 13:15Lunch break 
13:15 - 14:30Poster walk 2
14:30 - 16:00Session 07: The future of immunotherapy
 Chairs: S. Burdach, Munich (DE); S. Heitzeneder, Palo Alto (US)
14:30 - 15:00Keynote Lecture 07. From pathophysiology to targeted therapy of inherited diseases of the immune system including predisposition to lymphomas
A. Fischer, Paris (FR)
15:00 - 15:15S07.1 Novel adapter chimeric antigen receptor T-cells (aCAR-Ts) for temporally controllable targeting of multiple antigens
C. Seitz, Tübingen (DE)
15:15 - 15:30S07.2 CAR T-cells targeting pan-cancer antigen B7-H3 (CD276) demonstrate potent preclinical activity in pediatric medulloblastoma
S. Heitzeneder, Palo Alto (US)
15:30 - 15:45S07.3 Novel concepts and alternatives to CAR-T cells for pediatric cancer immunotherapy
M. Farlik, Vienna (AT)
15:45 - 16:00S07.4 Induction of HLA and PD-L1 by IFNg can sensitize refractory Ewing sarcoma to T cell checkpoint inhibition during treatment with TCR transgenic T cells
S. Burdach, Munich (DE)
16:00 - 16:30Coffee break
16:30 - 18:00Session 08: Next generation diagnostics
 Chairs: G. Schleiermacher, Paris (FR); K. Byrgazov, Vienna (AT)
16:30 - 17:00Keynote Lecture 08. Clonal evolution in pediatric solid high risk cancers based on sequential analysis of circulating tumor DNA
G. Schleiermacher, Paris (FR)
17:00 - 17:15S08.1 The Iceberg Map of germline mutations that predispose to cancers in children and adolescents - Network analyses with focus on primary immunodeficiencies
M. Seidel, Graz (AT)
17:15 - 17:30S08.2 Disseminated tumor cells (DTC) of stage M neuroblastoma patients undergo transcriptional alterations during disease progression - RNA-seq and first steps towards DTC-derived zebrafish xenografts
F. Rifatbegovic, Vienna (AT)
17:30 - 17:45S08.3  Risk prediction based on post induction bone marrow response and genomic profile: a future way to stratify stage M neuroblastoma patients?
S. Fiedler, Vienna (AT)
17:45 - 18:00S08.4 High CD371 cell surface expression is a characteristic feature of DUX4-rearranged B-cell precursor acute lymphoblastic leukemia
S. Strehl, Vienna (AT)
18:00Closing remarks


Scott A. Armstrong, MD, PhD

Dana-Farber Cancer Institute
Boston Children's Hospital, Harvard Medical School,
Broad Institute of MIT and Harvard, Boston, USA

Alain Fischer, Prof. MD

Hôpital Necker Enfants Malades Imagine Institute,
College de France, Paris, France

David Gisselsson, Prof.

Lund University
Divisions of Clinical Genetics and Pathology,
Lund, Sweden


Shai Izraeli, Prof.

Pediatric Hematology-Oncology, Schneider Children’s Medical Center, Petach Tikvah, Israel, and Sackler Faculty of Medicine, Tel Aviv University, Israel

David M. Langenau, PhD

Massachusetts General Hospital Research Institute
Harvard Medical School, Boston, USA

Martin A. Novak, PhD, Univ. Prof.
Professor of Mathematics and of Biology Dir.
Program for Evolutionary Dynamics
Harvard University
Cambr., Massachusetts, USA
Photo Credit: Sharona Jacobs


Gudrun Schleiermacher, MD PhD

Integrated Pediatric Oncology Center SIREDO
Department of Pediatric Oncology and INSERM U830
Institut Curie, Paris, France

Adam Shlien, PhD
The Hospital for Sick Children Toronto, Canada